The U.S. Food and Drug Administration has declined to approve Summit Therapeutics’ lung cancer drug ivonescimab, after a late-stage trial failed to establish a statistically significant improvement in how long patients lived. The decision was communicated through a complete response letter on Sunday, November 15, according to Reuters.
Ivonescimab was being developed for patients whose cancer had progressed after earlier treatments. In the study reviewed by the agency, the drug was administered with chemotherapy and reduced the risk of disease progression or death by 48% compared with chemotherapy alone. That result showed a benefit on progression-free survival, but the trial’s primary analysis did not meet the required statistical standard for overall survival.
Why the FDA rejected the application
Progression-free survival measures the time before a cancer worsens or a patient dies. Overall survival measures how long patients live after beginning treatment. Although the trial produced a significant delay in disease progression, the FDA determined that this result by itself did not establish a favorable benefit-risk profile for approval.
| Measure | Finding reported for ivonescimab |
|---|---|
| Trial setting | Late-stage study in patients with lung cancer |
| Treatment comparison | Ivonescimab plus chemotherapy versus chemotherapy alone |
| Progression or death | Risk reduced by 48% |
| Overall survival | No statistically significant improvement in the primary analysis |
Summit later gave the FDA updated survival information that the company said showed a consistent improvement among patients in both Asian and Western groups. The company’s submission therefore included follow-up analyzes intended to address the original survival result. The FDA’s action indicates that those materials did not overcome the agency’s concern that the application had not demonstrated a sufficiently clear overall-survival benefit.
“The subsequently matured OS dataset, consistency between Western and Asian patients, lack of new safety signals, and management’s previously characterized constructive regulatory interactions strengthen the package versus the original analysis,” TD Cowen analysts said earlier this month.
Ivonescimab is designed to act on two biological targets. It blocks PD-1, a protein involved in the ability of cancer to evade immune defenses, and VEGF, which tumors use to form blood vessels. The treatment was intended to combine those mechanisms with chemotherapy, but the FDA’s decision leaves the drug without approval for the application under review.
A setback for Summit’s licensing strategy
Summit obtained rights to ivonescimab in the United States, Canada, Europe and Japan from China’s Akeso in 2022. The agreement was valued at up to $5 billion, while Akeso retained rights in China. The FDA decision now represents a setback for Summit’s effort to expand its oncology portfolio in major Western markets.
- Agency action: The FDA issued a complete response letter and declined approval.
- Key trial result: The combination reduced the risk of progression or death by 48% versus chemotherapy alone.
- Main limitation: The primary analysis did not show a statistically significant overall-survival improvement.
The decision concerns the evidence submitted for this marketing application and should not be read as a finding that the drug had no effect on disease progression. Rather, the FDA concluded that the progression-free-survival result did not, on its own, provide the evidence needed to support approval when the study failed to confirm a statistically significant overall-survival benefit.